Swedbank AB Decreases Stock Holdings in Medpace Holdings, Inc. $MEDP

Key Points

• Swedbank AB has reduced its holdings in Medpace Holdings, Inc. by 12.1%, now owning 68,000 shares worth approximately $20.7 million.
• Several hedge funds have made significant moves regarding their positions in Medpace, with Mawer Investment Management purchasing a new position worth $212 million and Jacobs Levy Equity Management increasing its stake by 675.8%.
• Medpace reported a 14.2% year-over-year increase in revenue for the last quarter, achieving earnings per share of $3.10, exceeding analysts' expectations.

Swedbank AB trimmed its position in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 12.1% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 68,000 shares of the company's stock after selling 9,400 shares during the quarter. Swedbank AB owned 0.24% of Medpace worth $20,719,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently made changes to their positions in MEDP. Mawer Investment Management Ltd. purchased a new position in shares of Medpace in the first quarter worth $212,131,000. Vulcan Value Partners LLC increased its stake in shares of Medpace by 221.6% in the first quarter. Vulcan Value Partners LLC now owns 325,916 shares of the company's stock worth $99,159,000 after buying an additional 224,578 shares during the period. Spyglass Capital Management LLC increased its stake in shares of Medpace by 85.1% in the fourth quarter. Spyglass Capital Management LLC now owns 262,660 shares of the company's stock worth $87,264,000 after buying an additional 120,778 shares during the period. Jacobs Levy Equity Management Inc. increased its stake in shares of Medpace by 675.8% in the first quarter. Jacobs Levy Equity Management Inc. now owns 121,464 shares of the company's stock worth $37,009,000 after buying an additional 105,807 shares during the period. Finally, Invesco Ltd. boosted its holdings in Medpace by 9.4% in the first quarter. Invesco Ltd. now owns 1,186,768 shares of the company's stock valued at $361,596,000 after acquiring an additional 102,015 shares in the last quarter. 77.98% of the stock is owned by hedge funds and other institutional investors.

Medpace Trading Down 1.4%

Shares of MEDP stock opened at $490.64 on Monday. Medpace Holdings, Inc. has a 12 month low of $250.05 and a 12 month high of $501.30. The stock has a market cap of $13.78 billion, a PE ratio of 36.48, a price-to-earnings-growth ratio of 3.09 and a beta of 1.44. The company's fifty day moving average price is $429.46 and its 200-day moving average price is $349.43.

Medpace (NASDAQ:MEDP - Get Free Report) last announced its earnings results on Monday, July 21st. The company reported $3.10 EPS for the quarter, beating analysts' consensus estimates of $3.00 by $0.10. The firm had revenue of $603.31 million for the quarter, compared to analysts' expectations of $537.70 million. Medpace had a net margin of 18.74% and a return on equity of 67.66%. The company's quarterly revenue was up 14.2% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.75 EPS. Medpace has set its FY 2025 guidance at 13.760-14.53 EPS. On average, sell-side analysts forecast that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts recently weighed in on the stock. Barclays lifted their price target on shares of Medpace from $300.00 to $450.00 and gave the company an "equal weight" rating in a report on Wednesday, July 23rd. UBS Group cut shares of Medpace from a "neutral" rating to a "sell" rating and lifted their price target for the company from $300.00 to $305.00 in a report on Tuesday, July 29th. Jefferies Financial Group lifted their price target on shares of Medpace from $400.00 to $450.00 and gave the company a "hold" rating in a report on Tuesday, September 9th. Cowen cut shares of Medpace from a "buy" rating to a "sell" rating in a report on Wednesday, July 23rd. Finally, Rothschild Redb cut shares of Medpace from a "strong-buy" rating to a "hold" rating in a report on Wednesday, September 3rd. Two research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and three have given a Sell rating to the company. Based on data from MarketBeat.com, Medpace presently has a consensus rating of "Reduce" and a consensus target price of $422.27.

Insider Transactions at Medpace

In other news, General Counsel Stephen P. Ewald sold 3,000 shares of Medpace stock in a transaction dated Monday, July 28th. The stock was sold at an average price of $450.00, for a total value of $1,350,000.00. Following the completion of the transaction, the general counsel owned 10,343 shares of the company's stock, valued at $4,654,350. The trade was a 22.48% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Kevin M. Brady sold 12,000 shares of Medpace stock in a transaction dated Thursday, July 24th. The stock was sold at an average price of $454.23, for a total value of $5,450,760.00. Following the completion of the transaction, the chief financial officer directly owned 6,000 shares of the company's stock, valued at approximately $2,725,380. This represents a 66.67% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 161,266 shares of company stock worth $74,111,427 over the last quarter. Corporate insiders own 20.30% of the company's stock.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.